


To achieve consistent, relatively low-risk, capital and income growth by investing in UK equities. The Fund aims to invest in good quality companies with strong profit growth prospects - but only if their share valuation can be justified by these prospects.
| Name | % Net Assets |
|---|---|
| BG Group | 5.5% |
| GlaxoSmithKline | 5.4% |
| AstraZeneca | 4.8% |
| Vodafone | 4.8% |
| BP | 4.5% |
| Royal Dutch Shell | 4.2% |
| HSBC | 3.0% |
| Barclays PLC | 2.6% |
| BT Group | 2.6% |
| Rio Tinto | 2.2% |
| Key | % Net Assets |
|---|---|
| 5.5% | |
| 5.4% | |
| 4.8% | |
| 4.8% | |
| 79.5% |
| Date | 02-Mar-2022 |
|---|---|
| NAV | 733.50p |
| Currency | GBP |
| Change | -13.90p |
| % | -1.86% |
| YTD change | 733.50p |
| YTD % | n/a |
| Fund Inception | 19/11/1969 |
|---|---|
| Fund Manager | Humphrey Van Der Klugt |
| TER | 1.67 (20-Jun-2012) |
| Minimum Investment | |
|---|---|
| Initial | £1000 |
| Additional | n/a |
| Savings | £50 |
| Charges | |
|---|---|
| Initial | 5.25% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.02 |
| Sharpe ratio | 0.10 |
You are here: research